Skip to main content
Premium Trial:

Request an Annual Quote

Not Much of a Choice, Anyway

With credit tight and investors skittish, a hostile takeover of Genentech by Roche might not be that big of a deal, says an article in the San Jose Mercury News. And in any case, it's possible Genentech employees won't have many options these days when it comes to finding other jobs. Amid all the talk is a concern that a buyout would result in a loss of Genentech's renowned culture of independence and creativity, and an exodus of employees. Derek Lowe thinks that it will probably end up being difficult at best. The atmosphere of the acquiring company is going to seep in no matter what, he says, and keeping things small is a definite plus when it comes to productivity in drug discovery. "Overall, it really does help to know that you really do have to deliver, that there's no net down there, no one waiting to cushion the blow. It doesn't make things fun, not necessarily, but it does make them more productive."

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.